Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Fundamental Analysis

EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR

1.97  +0.01 (+0.41%)

Fundamental Rating

2

ALCJ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Health Care Equipment & Supplies industry. ALCJ may be in some trouble as it scores bad on both profitability and health. ALCJ has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALCJ has reported negative net income.
In the past year ALCJ has reported a negative cash flow from operations.
In the past 5 years ALCJ always reported negative net income.
In the past 5 years ALCJ always reported negative operating cash flow.
ALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFALCJ.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

ALCJ has a worse Return On Assets (-31.63%) than 78.18% of its industry peers.
The Return On Equity of ALCJ (-593.99%) is worse than 85.45% of its industry peers.
Industry RankSector Rank
ROA -31.63%
ROE -593.99%
ROIC N/A
ROA(3y)-32.8%
ROA(5y)-31.4%
ROE(3y)-377.91%
ROE(5y)-284%
ROIC(3y)N/A
ROIC(5y)N/A
ALCJ.PA Yearly ROA, ROE, ROICALCJ.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

ALCJ has a Gross Margin of 993.79%. This is amongst the best in the industry. ALCJ outperforms 100.00% of its industry peers.
ALCJ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 993.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCJ.PA Yearly Profit, Operating, Gross MarginsALCJ.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ALCJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCJ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALCJ has more shares outstanding
The debt/assets ratio for ALCJ is higher compared to a year ago.
ALCJ.PA Yearly Shares OutstandingALCJ.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ALCJ.PA Yearly Total Debt VS Total AssetsALCJ.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 0.38, we must say that ALCJ is in the distress zone and has some risk of bankruptcy.
ALCJ has a Altman-Z score of 0.38. This is in the lower half of the industry: ALCJ underperforms 65.45% of its industry peers.
A Debt/Equity ratio of 11.67 is on the high side and indicates that ALCJ has dependencies on debt financing.
The Debt to Equity ratio of ALCJ (11.67) is worse than 85.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 11.67
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACCN/A
WACC7.3%
ALCJ.PA Yearly LT Debt VS Equity VS FCFALCJ.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.58 indicates that ALCJ should not have too much problems paying its short term obligations.
ALCJ has a Current ratio (1.58) which is in line with its industry peers.
A Quick Ratio of 0.89 indicates that ALCJ may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.89, ALCJ is in line with its industry, outperforming 47.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 0.89
ALCJ.PA Yearly Current Assets VS Current LiabilitesALCJ.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ALCJ have decreased by -1.92% in the last year.
Looking at the last year, ALCJ shows a very negative growth in Revenue. The Revenue has decreased by -71.00% in the last year.
EPS 1Y (TTM)-1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.25%
Revenue 1Y (TTM)-71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALCJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.99% yearly.
The Revenue is expected to grow by 88.04% on average over the next years. This is a very strong growth
EPS Next Y33.19%
EPS Next 2Y72.01%
EPS Next 3Y52.99%
EPS Next 5YN/A
Revenue Next Year3.06%
Revenue Next 2Y110.41%
Revenue Next 3Y88.04%
Revenue Next 5YN/A

3.3 Evolution

ALCJ.PA Yearly Revenue VS EstimatesALCJ.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
ALCJ.PA Yearly EPS VS EstimatesALCJ.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALCJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 5.70, which indicates a rather cheap valuation of ALCJ.
Based on the Price/Forward Earnings ratio, ALCJ is valued cheaply inside the industry as 94.55% of the companies are valued more expensively.
ALCJ is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.7
ALCJ.PA Price Earnings VS Forward Price EarningsALCJ.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCJ.PA Per share dataALCJ.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALCJ's earnings are expected to grow with 52.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.01%
EPS Next 3Y52.99%

More info and screens

0

5. Dividend

5.1 Amount

ALCJ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CROSSJECT

EPA:ALCJ (3/7/2025, 7:00:00 PM)

1.97

+0.01 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-24 2024-09-24
Earnings (Next)03-31 2025-03-31/amc
Inst Owners0.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap91.07M
Analysts84.44
Price Target4.13 (109.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.16%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.7
P/S 628.09
P/FCF N/A
P/OCF N/A
P/B 51.63
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)0.35
Fwd EY17.54%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.04
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.63%
ROE -593.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 993.79%
FCFM N/A
ROA(3y)-32.8%
ROA(5y)-31.4%
ROE(3y)-377.91%
ROE(5y)-284%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 11.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 168.89%
Cap/Sales 3028.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 0.89
Altman-Z 0.38
F-Score3
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)152.85%
Cap/Depr(5y)140.85%
Cap/Sales(3y)1954.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.25%
EPS Next Y33.19%
EPS Next 2Y72.01%
EPS Next 3Y52.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year3.06%
Revenue Next 2Y110.41%
Revenue Next 3Y88.04%
Revenue Next 5YN/A
EBIT growth 1Y6.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.09%
EBIT Next 3Y63.55%
EBIT Next 5YN/A
FCF growth 1Y-6.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.91%
OCF growth 3YN/A
OCF growth 5YN/A